-
公开(公告)号：EP2671582B1
公开(公告)日：2016-07-13
申请号：EP12742448.9
申请日：2012-02-01
发明人： SAWADA, Takashi , DANJO, Tomohiro , MOTOSAWA, Keiichi , FURUTA, Takayuki , ICHIOKA, Maki , SUGAWARA, Masamori , UESAKA, Noriaki
IPC分类号： A61K31/4184 , A61K31/42 , A61K31/4355 , A61K31/4439 , A61K31/4525 , A61K31/497 , A61K31/519 , A61P17/04 , A61P43/00 , C07D471/04 , C07D487/04
CPC分类号： C07D471/04 , A61K31/4184 , A61K31/42 , A61K31/4355 , A61K31/4439 , A61K31/4525 , A61K31/497 , A61K31/519 , C07D487/04 , C07D519/00
-
公开(公告)号：EP3378860A1
公开(公告)日：2018-09-26
申请号：EP18167805.3
申请日：2010-04-28
IPC分类号： C07D417/14 , A61K31/435 , A61K31/4355 , A61K31/436 , A61K31/4365 , A61K31/4439 , A61K31/4709 , A61K31/506 , A61K31/5377 , A61P25/14 , A61P25/16 , A61P43/00 , C07D491/048 , C07D491/052 , C07D495/04 , A61K31/198 , A61K31/427
CPC分类号： C07D495/04 , A61K31/198 , A61K31/427 , A61K31/435 , A61K31/4355 , A61K31/436 , A61K31/4365 , A61K31/4439 , A61K31/4709 , A61K31/506 , A61K31/5377 , C07D417/14 , C07D491/048 , C07D491/052
摘要： The present invention, amongst others, relates to a pharmaceutical composition comprising (a) a thiazole derivative represented by the formula (I)
wherein R 1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R 2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof, and (b) L-DOPA and/or a dopamine agonist.-
公开(公告)号：EP2881394A1
公开(公告)日：2015-06-10
申请号：EP13826355.3
申请日：2013-07-31
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61P17/04 , A61P43/00
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/5377
摘要： The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like.
[wherein, R 1 represents optionally substituted lower alkyl and the like, R 2 represents optionally substituted lower alkyl and the like, R 3 represents the formula (II):
(wherein, n represents 0 or 1, R 3a represents a hydrogen atom and the like, R 3b represents a hydrogen atom and the like, and R 3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W 1 represents a nitrogen atom and the like, W 2 represents a nitrogen atom and the like]摘要翻译： 根据本发明的环稠合杂环化合物或其药学上可接受的盐具有T型钙通道调节作用，并且可用作例如用于治疗和/或预防瘙痒的药物。 本发明提供了具有T型钙通道调节作用的由以下通式（I）表示的环稠合杂环化合物或其药学上可接受的盐等，可用作治疗和/或预防剂 瘙痒等。 [其中，R 1表示任选取代的低级烷基等，R 2表示任选取代的低级烷基等，R 3表示式（II）：（其中，n表示0或1，R 3a表示氢原子， 类似物，R 3b表示氢原子等，R 3c表示氢原子等）等，Q表示氢原子等，W 1表示氮原子等，W 2 表示氮原子等]
-
公开(公告)号：EP2881394B1
公开(公告)日：2018-03-21
申请号：EP13826355.3
申请日：2013-07-31
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61P17/04 , A61P43/00
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/5377
摘要： The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R 1 represents optionally substituted lower alkyl and the like, R 2 represents optionally substituted lower alkyl and the like, R 3 represents the formula (II): (wherein, n represents 0 or 1, R 3a represents a hydrogen atom and the like, R 3b represents a hydrogen atom and the like, and R 3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W 1 represents a nitrogen atom and the like, W 2 represents a nitrogen atom and the like]
-
公开(公告)号：EP2090570B1
公开(公告)日：2011-11-09
申请号：EP07828189.6
申请日：2007-09-05
发明人： OSAKADA, Naoto , OSAKADA, Mariko , SAWADA, Takashi , KANEKO, Satoshi , MIZUTANI, Atsuko , UESAKA, Noriaki , NAKASATO, Yoshisuke , KATAYAMA, Keishi , SUGAWARA, Masamori , KITAMURA, Yushi
IPC分类号： C07D233/58
CPC分类号： C07D233/64 , C07D401/04 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： Disclosed is a CB2 receptor modulator or the like containing an imidazole derivative represented by the general formula (I) below or a pharmaceutically acceptable salt thereof as an active ingredient. (I) [In the formula, R1 represents an optionally substituted lower alkyl group or the like; R2 represents an optionally substituted cycloalkyl or the like; R3 represents an optionally substituted aryl or the like; and n represents an integer of 0-3.]
-
公开(公告)号：EP2070927A1
公开(公告)日：2009-06-17
申请号：EP07807200.6
申请日：2007-09-13
发明人： SAWADA, Takashi , OSAKADA, Naoto , KANEKO, Satoshi , MIZUTANI, Atsuko , UESAKA, Noriaki , KATAYAMA, Keishi
IPC分类号： C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/519 , A61P1/04 , A61P3/00 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P17/04 , A61P19/02 , A61P19/10 , A61P25/00 , A61P25/06 , A61P27/06 , A61P27/16 , A61P29/00 , A61P37/00 , A61P37/08 , A61P43/00
CPC分类号： C07D471/04 , C07D487/04
摘要： A fused heterocycle derivative represented by the general formula (I):
(wherein R 1 represents optionally substituted lower alkyl, or the like; R 2 represents an optionally substituted aliphatic heterocyclic group, or the like; R 3 represents -C(=Z)NR 5 R 6 (wherein R 5 and R 6 represent optionally substituted lower alkyl, or the like, and Z represents an oxygen atom or the like), or the like; n represents an integer of 1 to 3; and W represents C-R 5 (wherein R 5 represents a hydrogen atom or the like)) or a pharmaceutically acceptable salt thereof, and the like are provided.摘要翻译： 由通式（I）表示的稠合杂环衍生物：其中R 1表示任选取代的低级烷基等; R 2表示任选取代的脂族杂环基等; R 3表示-C（= Z） NR 5 R 6（其中R 5和R 6表示任选取代的低级烷基等，Z表示氧原子等）等; n表示1〜3的整数，W表示CR 5 （其中R 5表示氢原子等））或其药学上可接受的盐等。
-
公开(公告)号：EP1921077B1
公开(公告)日：2017-07-26
申请号：EP06782197.5
申请日：2006-08-02
IPC分类号： C07D417/14 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/5377 , A61P25/20
CPC分类号： C07D417/14 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/5377
-
公开(公告)号：EP1700856B1
公开(公告)日：2015-11-11
申请号：EP04808128.5
申请日：2004-12-24
发明人： NAKAJIMA, Takao , SUGAWARA, Masamori , UCHIDA, Shin-ichi , OHNO, Tetsuji , NOMOTO, Yuji , UESAKA, Noriaki , NAKASATO, Yoshisuke
IPC分类号： C07D417/04
CPC分类号： C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要： (Wherein n is an integer of from 0 to 3; R 1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R 2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, -COR 8 , or the like; R 3 and R 4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, -COR 12 , or the like) For example, provided are adenosine A 2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.
-
公开(公告)号：EP2671582A1
公开(公告)日：2013-12-11
申请号：EP12742448.9
申请日：2012-02-01
发明人： SAWADA, Takashi , DANJO, Tomohiro , MOTOSAWA, Keiichi , FURUTA, Takayuki , ICHIOKA, Maki , SUGAWARA, Masamori , UESAKA, Noriaki
IPC分类号： A61K31/4184 , A61K31/42 , A61K31/4355 , A61K31/4439 , A61K31/4525 , A61K31/497 , A61K31/519 , A61P17/04 , A61P43/00 , C07D471/04 , C07D487/04
CPC分类号： C07D471/04 , A61K31/4184 , A61K31/42 , A61K31/4355 , A61K31/4439 , A61K31/4525 , A61K31/497 , A61K31/519 , C07D487/04 , C07D519/00
摘要： A ring-fused heterocyclic derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof having a T-type calcium channel regulatory effect and useful as a pruritus therapeutic and/or preventive agent, and the like are provided. In the general formula (I), R 1 represents optionally substituted lower alkyl, and the like; R 2 represents an optionally substituted cycloalkyl, and the like; Q represents a hydrogen atom, and the like; R 3 represents -C(=O)NR 8 R 9 (wherein R 8 and R 9 may be the same or different, and each represents a hydrogen atom, and the like), and the like; L 1 represents -CR 11A R 11B - (wherein R 11A and R 11B may be the same or different, and each represents a hydrogen atom, and the like), and the like; and W 1 and W 2 may be the same or different, and each represents C-R 12 (wherein R 12 represents a hydrogen atom, and the like), and the like.
摘要翻译： 提供由具有T型钙通道调节作用并可用作瘙痒治疗和/或预防剂的由以下通式（I）表示的环稠合杂环衍生物或其药学上可接受的盐。 在通式（I）中，R 1表示任选取代的低级烷基等; R 2表示任选取代的环烷基等; Q表示氢原子等; R 3表示-C（= O）NR 8 R 9（其中R 8和R 9可以相同或不同，各自表示氢原子等）等; L 1表示-CR 11A R 11B - （其中，R 11A和R 11B可以相同或不同，各自表示氢原子等）等。 W 1和W 2可以相同或不同，各自表示C-R 12（其中，R 12表示氢原子等）等。
-
公开(公告)号：EP2090570A1
公开(公告)日：2009-08-19
申请号：EP07828189.6
申请日：2007-09-05
发明人： OSAKADA, Naoto , OSAKADA, Mariko , SAWADA, Takashi , KANEKO, Satoshi , MIZUTANI, Atsuko , UESAKA, Noriaki , NAKASATO, Yoshisuke , KATAYAMA, Keishi , SUGAWARA, Masamori , KITAMURA, Yushi
IPC分类号： C07D233/58
CPC分类号： C07D233/64 , C07D401/04 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I):
[wherein, R 1 represents optionally substituted lower alkyl or the like; R 2 represents optionally substituted cycloalkyl or the like; R 3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.摘要翻译： 包含由通式（I）表示的咪唑衍生物的CB2受体调节剂：[其中，R 1表示任选取代的低级烷基等; R 2表示任选取代的环烷基等; R 3表示任选取代的芳基等; 和n表示0〜3的整数]或其药学上可接受的盐作为有效成分。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.032 秒)
